Home | Welcome to Contract Pharma   
Last Updated Wednesday, June 3 2015

Print RSS Feed

Search Results for 'Phase III'

Search For:
Refine by Dates:
From: To:
Past 7 Days        Past 30 Days
Refine By Content:

Contract Service Directory Companies

View All Companies »


Contract Service Directory Categories

View All Categories »


Search Results:

Published June 2, 2015
Will evaluate investigational candidates in cancer patients Read More »
By Tim Wright, Editor
Published June 2, 2015
PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market Read More »
Challenges in Global Biosimilar Development: A Regulatory Perspective
By Patricia Hurley, Joan Boren and Costantino Congiatu, PPD
Published June 2, 2015
More than $60 billion worth of patents on biological products are expiring before 2020, representing a major opportunity for the pharmaceutical industry. Read More »
Published June 1, 2015
Will focus on exploring potential combinations of PS-targeting agents Read More »
Published May 11, 2015
The new facility has already been deployed to manufacture a Humira biosimilar candidate in an upcoming Phase III trial Read More »
Published May 6, 2015
Hare brings 28 years of experience in the biopharma and CROs industries Read More »
Published April 23, 2015
Initiates Phase III Trial Read More »
Published April 14, 2015
Completes production of a commercial scale lot of EVK-001 in accordance with CMC Read More »
Published April 13, 2015
Diversifies development risk with second, complementary acute pain product Read More »
Published April 13, 2015
New website has been launched at www.juniperpharma.com Read More »
Published April 8, 2015
Drs. Rozenman and Holfinger to oversee Phase III trial of lead product, AR 101 Read More »
Published April 1, 2015
Granted authorization to produce lentiviral vectors for clinical use and CAR-T cell therapies Read More »
Published March 30, 2015
Expands CNS franchise Read More »
Published March 26, 2015
Fully operational to supply comprehensive immunotherapeutic treatments Read More »
Published March 23, 2015
Introduces new corporate identity and logo Read More »
Published March 19, 2015
Will perform tech transfer and support clinical trial for ICT-107 Read More »
Published March 16, 2015
To discover and develop anti-cancer immunotherapies Read More »
Published March 6, 2015
Advances Phase III Evaluation of SMNRx Read More »
By Brigitte de Lima, Results Healthcare
Published March 6, 2015
A huge opportunity for savvy service providers Read More »
Consolidation in Outsourcing
By Michael A. Martorelli , Director, Fairmount Partners
Published March 6, 2015
Reviewing 2014’s M&A activity Read More »
Published March 4, 2015
Gains exclusive option to license the Phase III prostate cancer immunotherapy Read More »
Published February 25, 2015
Opens newly expanded office Read More »
Published February 24, 2015
Gains Phase III drug for gastrointestinal disease Read More »
Published February 23, 2015
Merck to purchase 15% equity stake in NGM Read More »
Published February 20, 2015
AMPLEX and PREFIX are ready for Phase III Read More »
Published February 19, 2015
Will use LymPro test to evaluate lead drug candidate combination Read More »
Published February 4, 2015
Phase II trial shows progression-free survival in beast cancer Read More »
Published February 2, 2015
Mylan to manufacture TD-4208 and will lead commercialization in the U.S. Read More »
Supplier Selection: A Roadmap to a Good Start
By George Tyson, CMC and supply chain consultant
Published January 29, 2015
Good supplier selection is a key element of success in the pharmaceutical industry today. Read More »
Published January 14, 2015
Gains exclusive rights to Phase III immuno-oncology compound Read More »
Published January 6, 2015
Sarecycline advances to Phase III trials Read More »
Published January 6, 2015
Will support manufacturing and production of Argos immunotherapies Read More »
Published December 30, 2014
First once-daily human (GLP-1) analogue shown to result in greater weight loss Read More »
Published December 16, 2014
License agreement includes foam vehicle for Azelaic Acid Read More »
Published December 15, 2014
Aims to develop and commercialize long-acting hGH-CTP for growth hormone deficiency Read More »
Published November 24, 2014
Aims to develop, manufacture, and distribute NewLink's rVSV-EBOV candidate Read More »
Published November 20, 2014
Enrolls first patient in Phase III linaclotide trial Read More »
Published November 18, 2014
Issuance of Patent 8,859,530 covers co-administration of steroids and zoledronic acid related to novel investigational therapy for controlling osteoarthritis. Read More »
Published November 17, 2014
Ong brings extensive drug development experience Read More »
Published October 28, 2014
Gains exclusive option to acquire F-star Alpha and lead anti-cancer asset Read More »
Published October 24, 2014
Daratumumab Phase III multiple myeloma trial advances Read More »
Published October 14, 2014
Will undertake a regulatory document inventory and evaluation of Provectus’ information management system Read More »
Newsmakers: Cell Therapies Look to Change the Paradigm of Drug Products
By Kristin Brooks, Associate Editor
Published October 14, 2014
While expensive and difficult to produce, Big Pharma is investing, looking to overcome the obstacles to development and commercialization that remain Read More »
Published October 3, 2014
Tabalumab fails to meet efficacy expectations Read More »
Published September 29, 2014
Gains Phase III AML candidate quizartinib Read More »
Published September 24, 2014
Baxter gains ex-U.S. rights to Phase III, orphan pancreatic cancer drug Read More »
Published September 15, 2014
Ho to lead clinical development, regulatory and translational medicine functions Read More »
Published September 10, 2014
Genmab to pay $11 million for exclusive rights to Seattle Genetics' ADC technology Read More »
Published September 9, 2014
Adds capsule bander for liquid filling and a second capsule filling machine Read More »
Clinical Trial Supplies 101: An Outsourcing Primer for Virtual Pharma and Biopharma Companies, Part1
By Joseph Iacobucci and Damian Gant , Clinical Supplies and Xcelience
Published September 8, 2014
Getting packaged investigational materials dispensed to the patients taking part in clinical trials, on time and correctly, requires orchestrating myriad activities. Outsourcing makes the process even more complex. This series of articles presents tips on how to do it right. Read More »


Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On